Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Farmer, Hannah, McCabe, Nuala, Lord, Christopher J., Tutt, Andrew N. J., Johnson, Damian A., Richardson, Tobias B., Santarosa, Manuela, Dillon, Krystyna J., Hickson, Ian, Knights, Charlotte, Martin, Niall M. B., Jackson, Stephen P., Smith, Graeme C. M., Ashworth, Alan·2005·Nature

DOI 10.1038/nature03445

Cited by (1,042)

Items 901–1,000 of 1,042

Structure-Based DNA-Targeting Strategies with Small Molecule Ligands for Drug Discovery
Jia Sheng, Jianhua Gan, Zhen Huang · 2013 · Medicinal Research Reviews
Tumor Suppressor CHK2: Regulator of DNA Damage Response and Mediator of Chromosomal Stability
Ailine Stolz, Norman Ertych, Holger Bastians · 2010 · Clinical Cancer Research
Links between genome integrity and BRCA1 tumor suppression
Mischa Li Covington, Roger A. Greenberg · 2012 · Trends in Biochemical Sciences
Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer
Andrea Bisso, Michela Faleschini, Federico Zampa, Valeria Capaci, Jacopo De Santa, Libero Santarpia, Silvano Piazza, Vera Cappelletti, Maria Grazia Daidone, Reuven Agami et al. · 2013 · Cell Cycle
Mitoxantrone Targets Human Ubiquitin-Specific Peptidase 11 (USP11) and Is a Potent Inhibitor of Pancreatic Cancer Cell Survival
Richard Andrew Burkhart, Peng Yu, Zoë A. Norris, Renée M. Tholey, Vanessa A. Talbott, Qin Liang, Yongxing Ai, Kathy Miller, Shruti Lal, Joseph A. Cozzitorto et al. · 2013 · Molecular Cancer Research
Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP
Yuan Yuan, Yu-Min Liao, Chung-Tsen Hsueh, Hamid Mirshahidi · 2011 · Journal of Hematology & Oncology
Development of synthetic lethality in cancer: molecular and cellular classification
Shijie Li, Win Topatana, Sarun Juengpanich, Jiasheng Cao, Jiahao Hu, Bin Zhang, Diana Ma, Xiujun Cai, Mingyu Chen · 2020 · Signal Transduction and Targeted Therapy
Discovery of synthetic lethal and tumor suppressor paralog pairs in the human genome
Phoebe C. R. Parrish, James D. Thomas, Austin M. Gabel, Shriya Kamlapurkar, Robert K. Bradley, Alice H. Berger · 2021 · Cell Reports
Inhibitors of PARP: Number crunching and structure gazing
Johannes Rudolph, Karen Jung, Karolin Luger · 2022 · Proceedings of the National Academy of Sciences
Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations
Soley Bayraktar, Angelica M. Gutierrez‐Barrera, Diane Liu, Tunc Tasbas, Uǧur Akar, Jennifer Keating Litton, E. Lin, Constance T. Albarracin, Funda Meric‐Bernstam, Ana Maria Gonzalez-Angulo et al. · 2011 · Breast Cancer Research and Treatment
The splicing-factor related protein SFPQ/PSF interacts with RAD51D and is necessary for homology-directed repair and sister chromatid cohesion
Changanamkandath Rajesh, Dustin K. Baker, Andrew J. Pierce, Douglas L. Pittman · 2010 · Nucleic Acids Research
Advances and perspectives of PARP inhibitors
Yi, Ming, Dong, Bing, Qin, Shuang, Chu, Qian, Wu, Kongming, Luo, Suxia · 2019 · Experimental Hematology & Oncology
The Case for Proteomics and Phospho‐Proteomics in Personalized Cancer Medicine
Sophia Doll, Florian Gnad, Matthias Mann · 2019 · PROTEOMICS - CLINICAL APPLICATIONS
A Focused DNA-Encoded Chemical Library for the Discovery of Inhibitors of NAD + -Dependent Enzymes
Lik Hang Yuen, Srikanta Dana, Yu Liu, Samuel I. Bloom, A.G. Thorsell, Dario Neri, Anthony J. Donato, Dmitri Kireev, Herwig Schuler, Raphael M. Franzini · 2019 · Journal of the American Chemical Society
Endogenous DNA 3′ Blocks Are Vulnerabilities for BRCA1 and BRCA2 Deficiency and Are Reversed by the APE2 Nuclease
Alejandro Álvarez-Quilón, Jessica L. Wojtaszek, Marie‐Claude Mathieu, Tejas Patel, C. Denise Appel, Nicole Hustedt, Silvia Emma Rossi, Bret D. Wallace, Dheva Setiaputra, Salomé Adam et al. · 2020 · Molecular Cell
Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status
Joanne Kotsopoulos, Barry P. Rosen, Isabel Fan, Joel Moody, John R McLaughlin, Harvey A. Risch, Taymaa May, Ping Sun, Steven Alexander Narod · 2015 · Gynecologic Oncology
CtIP-mediated resection is essential for viability and can operate independently of BRCA1
Federica Polato, Elsa Callén, Nancy Wong, Robert B. Faryabi, Samuel F. Bunting, Hua Tang Chen, Marina Kozak, Michael J. Kruhlak, Colleen R. Reczek, Wen‐Hwa Lee et al. · 2014 · The Journal of Experimental Medicine
The Predominant Role of Surgery in the Prevention and New Trends in the Surgical Treatment of Women With BRCA1/2 Mutations
Michael Fatouros, Georgios Baltoyiannis, Dimitrios H Roukos · 2007 · Annals of Surgical Oncology
Disulfiram’s anti-cancer activity reflects targeting NPL4, not inhibition of aldehyde dehydrogenase
Skrott, Zdenek, Majera, Dusana, Gursky, Jan, Buchtova, Tereza, Hajduch, Marian, Mistrik, Martin, Bartek, Jiri · 2019 · Oncogene
Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer
Panagiotis A. Konstantinopoulos, Andrew J. Wilson, Jeanette L. Saskowski, Erica Wass, Dineo Khabele · 2014 · Gynecologic Oncology
The tandem duplicator phenotype as a distinct genomic configuration in cancer
Francesca Menghi, Koichiro Inaki, Xingyi Woo, Pooja Kumar, Krzysztof R. Grzȩda, Ankit Malhotra, Vinod Kumar Yadav, Hyunsoo Kim, Eladio J. Márquez, Duygu Ucar et al. · 2016 · Proceedings of the National Academy of Sciences
Analysis of PARP inhibitor toxicity by multidimensional fluorescence microscopy reveals mechanisms of sensitivity and resistance
Jone Michelena, Aleksandra Lezaja, Federico Teloni, Thomas Schmid, Ralph Imhof, Matthias Altmeyer · 2018 · Nature Communications
Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function
Bin Gui, Fu Gui, Tomoaki Takai, Chao Feng, Xiao Bai, Ladan Fazli, Xuesen Dong, Shuai Liu, Xiaofeng Zhang, Wei Zhang et al. · 2019 · Proceedings of the National Academy of Sciences
BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications
Carlo G. M. Messina, Carlo Cattrini, Davide Soldato, Giacomo Vallome, Orazio Caffo, Elena Castro, David Olmos, Francesco Boccardo, Elisa Zanardi · 2020 · Journal of Oncology
Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations
Sabine Schmid, Aurelius Gabriel Omlin, Celestia S. Higano, Christopher J. Sweeney, Nieves Martínez Chanzá, Niven Mehra, Malou C. P. Kuppen, Himisha Beltran, Vincenza Conteduca, Daniel Vargas Pivato de Almeida et al. · 2020 · JAMA Network Open
PARP Inhibitors: Clinical Limitations and Recent Attempts to Overcome Them
Dongha Kim, Hye Jin Nam · 2022 · International Journal of Molecular Sciences
PROTAC’ing oncoproteins: targeted protein degradation for cancer therapy
Jeremy M. Kelm, Deepti S. Pandey, Evan Malin, Hussein W. Kansou, Sahil Arora, Raj Kumar, Navnath S. Gavande · 2023 · Molecular Cancer
Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors
Yikai Luo, Yu Xia, Dan Liu, Xiong Li, Huayi Li, Jiahao Liu, Dongchen Zhou, Yu Jun Dong, Xin Li, Yiyu Qian et al. · 2024 · Cell
The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells
Banu Arun, Uǧur Akar, Angelica M. Gutierrez‐Barrera, Gabriel N. Hortobágyi, Bülent Özpolat · 2015 · International Journal of Oncology
Targeting DNA repair, DNA metabolism and replication stress as anti‐cancer strategies
Jordi Carreras Puigvert, Kumar Sanjiv, Thomas Helleday · 2015 · FEBS Journal
Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers
Chris Bryant, Rebecca Rawlinson, Andrew J. Massey · 2014 · BMC Cancer
The potential of exploiting DNA-repair defects for optimizing lung cancer treatment
Sophie C. Postel-Vinay, Elsa Vanhecke, Ken André Olaussen, Christopher J. Lord, Alan Ashworth, Jean‐Charles Soria · 2012 · Nature Reviews Clinical Oncology
Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90
Fiona A. Dungey, Keith W. Caldecott, Anthony J. Chalmers · 2009 · Molecular Cancer Therapeutics
Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells
Caroline V.M. Verhagen, Rosemarie de Haan, Floor Hageman, Tim P.D. Oostendorp, Annalisa L. E. Carli, Mark J. O’Connor, Jos Jonkers, Marcel Verheij, Michiel W. M. van den Brekel, Conchita Vens · 2015 · Radiotherapy and Oncology
Targeting cancer cells through autophagy for anticancer therapy
Sandra Turcotte, Amato J. Giaccia · 2010 · Current Opinion in Cell Biology
Nuclear poly(ADP-ribose) activity is a therapeutic target in amyotrophic lateral sclerosis
Leeanne McGurk, Jelena Mojsilovic‐Petrovic, Vivianna M. Van Deerlin, James Shorter, Robert Gordon Kalb, V. M. Lee, John Q. Trojanowski, E. B. Lee, Nancy M. Bonini · 2018 · Acta Neuropathologica Communications
Synthetically Lethal Interactions of ATM, ATR, and DNA-PKcs
Omar L. Kantidze, Artem K. Velichko, Artem V. Luzhin, Nadezhda V. Petrova, Sergey V. Razin · 2018 · Trends in cancer
Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol
Paul Lesueur, Justine Lequesne, Jean‐Michel Grellard, Audrey Emmanuelle Dugué, Elodie Coquan, Pierre-Emmanuel Brachet, Julien Geffrelot, William Kao, Évelyne Emery, David Hassanein Berro et al. · 2019 · BMC Cancer
Triple‑negative breast cancer: A run‑through of features, classification and current therapies (Review)
Meghana Manjunath, Bibha Choudhary · 2021 · Oncology Letters
Involvement of Polynucleotide Kinase in a Poly(ADP-ribose) Polymerase-1-dependent DNA Double-strand Breaks Rejoining Pathway
Marc Audebert, Bernard Salles, Michael Weinfeld, Patrick Calsou · 2005 · Journal of Molecular Biology
Targeting homologous recombination repair defects in cancer
Bastiaan Evers, Thomas Helleday, Jos Jonkers · 2010 · Trends in Pharmacological Sciences
Cooperation of the Cockayne Syndrome Group B Protein and Poly(ADP-Ribose) Polymerase 1 in the Response to Oxidative Stress
Tina Thorslund, Cayetano von Kobbe, Jeanine A. Harrigan, Fred Eliezer Indig, Mette Christiansen, Tinna Stevnsner, Vilhelm A. Bohr · 2005 · Molecular and Cellular Biology
Exploiting synthetic lethal interactions for targeted cancer therapy
Hans Christian Reinhardt, Hai Jiang, Michael T. Hemann, Michael B. Yaffe · 2009 · Cell Cycle
Predictive biomarkers for cancer therapy with PARP inhibitors
Judith Michels, Ilio Vitale, Murat K. Saparbaev, Maria Castedo, Guido Kroemer · 2013 · Oncogene
Phosphorylated RPA recruits PALB2 to stalled DNA replication forks to facilitate fork recovery
Anar Murphy, Michael Fitzgerald, Teresa Ro, Jee Hyun Kim, Ariana I. Rabinowitsch, Dipanjan Chowdhury, Carl L. Schildkraut, James A. Borowiec · 2014 · The Journal of Cell Biology
The biological effects and clinical implications of BRCA mutations: where do we go from here?
Dominique Stoppa‐Lyonnet · 2016 · European Journal of Human Genetics
PARP Trapping Beyond Homologous Recombination and Platinum Sensitivity in Cancers
Junko Murai, Yves G. Pommier · 2018 · Annual Review of Cancer Biology
The molecular landscape of Asian breast cancers reveals clinically relevant population-specific differences
Jia Wern Pan, Muhammad Mamduh Ahmad Zabidi, Pei-Sze Ng, Mei‐Yee Meng, Siti Norhidayu Hasan, Bethan Sandey, Stephen‐John Sammut, Cheng Har Yip, Pathmanathan Rajadurai, Oscar M. Rueda et al. · 2020 · Nature Communications
BRCA Mutations in Ovarian and Prostate Cancer: Bench to Bedside
Stergios Boussios, Elie Rassy, Michele Moschetta, Aruni Ghose, Sola Michael Adeleke, Elisabet Sanchez, Matin Sheriff, Cyrus Chargari, Nicholas A. Pavlidis · 2022 · Cancers
DNA Double Strand Break Repair: A Radiation Perspective
Joy N. Kavanagh, Kelly M. Redmond, Giuseppe Schettino, Kevin M. Prise · 2013 · Antioxidants and Redox Signaling
DNA Repair Proteins as Molecular Targets for Cancer Therapeutics
Mark R. Kelley, Melissa L. Fishel · 2008 · Anti-Cancer Agents in Medicinal Chemistry
A phosphorylation–deubiquitination cascade regulates the BRCA2–RAD51 axis in homologous recombination
Kuntian Luo, Lei Li, Yunhui Li, Chenming Wu, Yujiao Yin, Yuping Chen, Min Deng, Somaira Nowsheen, Jian Yuan, Zhenkun Lou · 2016 · Genes & Development
An update on PARP inhibitors for the treatment of cancer
Marcia Hall, Sarah Benafif · 2015 · OncoTargets and Therapy
The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer
Johanna Tommiska, Jiřina Bártková, Merja Heinonen, Laura C. Hautala, Outi Kilpivaara, Hannaleena Eerola, Kristiina Aittomäki, Barbara Hofstetter, Jiří Lukáš, Karl von Smitten et al. · 2007 · Oncogene
Therapeutic Potential of the Poly(ADP-ribose) Polymerase Inhibitor Rucaparib for the Treatment of Sporadic Human Ovarian Cancer
Maike Ihnen, Christine zu Eulenburg, Teodora R. Kolarova, Jing Wei Qi, Kanthinh Manivong, Meenal Chalukya, Judy Dering, Lee A. Anderson, Charles Ginther, Alexandra Meuter et al. · 2013 · Molecular Cancer Therapeutics
Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors
Charles‐André Philip, Ido Laskov, M.-C. Beauchamp, Maud Marques, Oreekha Amin, Joanna Bitharas, Roy Kessous, Liron Kogan, Tahira Baloch, Walter Henri Gotlieb et al. · 2017 · BMC Cancer
DNA Repair by Homologous Recombination, But Not by Nonhomologous End Joining, Is Elevated in Breast Cancer Cells
Zhiyong Mao, Ying Jiang, Xiang Liu, Andrei Seluanov, Vera A. Gorbunova · 2009 · Neoplasia
Health disparities in breast cancer: biology meets socioeconomic status
Barbara Karen Dunn, Tanya Agurs‐Collins, Doris Browne, Ronald A. Lubet, Karen A. Johnson · 2010 · Breast Cancer Research and Treatment
Doubling Down on the PI3K-AKT-mTOR Pathway Enhances the Antitumor Efficacy of PARP Inhibitor in Triple Negative Breast Cancer Model beyond BRCA-ness
Pradip K. De, Yuling Sun, Jennifer H. Carlson, Lori S. Friedman, Brian R Leyland-Jones, Nandini Dey · 2014 · Neoplasia
Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer
Larissa A. Korde, Lara Lusa, Lisa M. McShane, Peter F. Lebowitz, Luanne Lukes, Kevin A. Camphausen, Joel S. Parker, Sandra M. Swain, Kent W. Hunter, Jo Anne Zujewski · 2009 · Breast Cancer Research and Treatment
The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells
Silvana B. De Lorenzo, Anand G. Patel, Rachel M. Hurley, Scott H. Kaufmann · 2013 · Frontiers in Oncology
PARP3 affects the relative contribution of homologous recombination and nonhomologous end-joining pathways
Carole Beck, Christian Boehler, Josée Guirouilh‐Barbat, Marie-Elise Bonnet, Giuditta Illuzzi, Philippe Rondé, Laurent Gauthier, Najat Magroun, Anbazhagan Rajendran, Bernard S. López et al. · 2014 · Nucleic Acids Research
Cell Cycle–Targeted Cancer Therapies
Charles J. Sherr, Jiří Bártek · 2016 · Annual Review of Cancer Biology
Poly(ADP-ribose) polymerase enzymes and the maintenance of genome integrity
Travis Eisemann, John M. Pascal · 2019 · Cellular and Molecular Life Sciences
Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer
Michela Chiappa, Federica Guffanti, Francesco Bertoni, Ilaria Colombo, Giovanna L.M. Damia · 2021 · Drug Resistance Updates
Reduced Glutathione: A Radioprotector or a Modulator of DNA-Repair Activity?
Anupam Chatterjee · 2013 · Nutrients
CCT241533 Is a Potent and Selective Inhibitor of CHK2 that Potentiates the Cytotoxicity of PARP Inhibitors
Victoria E. Anderson, Michael I. Walton, Paul D. Eve, Katherine J. Boxall, Laurent Antoni, John Caldwell, Wynne Aherne, Laurence H. Pearl, Antony W. Oliver, Ian Collins et al. · 2011 · Cancer Research
Poly(ADP-Ribose) Polymerase-1 Inhibitor Treatment Regresses Autochthonous Brca2/p53 -Mutant Mammary Tumors In vivo and Delays Tumor Relapse in Combination with Carboplatin
Trevor Hay, James R. Matthews, Lucie Pietzka, Alan Lau, Aaron N. Cranston, Anders O.H. Nygren, Anthony G Douglas-Jones, Graeme C.M. Smith, Niall M.B. Martin, Mark J. O’Connor et al. · 2009 · Cancer Research
Hereditary Breast Cancer and the BRCA1-Associated FANCJ/BACH1/BRIP1
Cantor, Sharon B, Guillemette, Shawna · 2011 · Future Oncology
Synthesis and Evaluation of a New Generation of Orally Efficacious Benzimidazole-Based Poly(ADP-ribose) Polymerase-1 (PARP-1) Inhibitors as Anticancer Agents
Yunsong Tong, Jennifer J. Bouska, Paul A. Ellis, Eric Feral Johnson, Joel D. Leverson, Xuesong Liu, Patrick A. Marcotte, Amanda M. Olson, Donald J. Osterling, Magdalena Przytulinska et al. · 2009 · Journal of Medicinal Chemistry
Ferulic acid decreases cell viability and colony formation while inhibiting migration of MIA PaCa-2 human pancreatic cancer cells in vitro
Umut Fahrioğlu, Yavuz Dodurga, Levent Elmas, Mücahit Seçme · 2015 · Gene
Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy
Marieke A. Vollebergh, Esther H. Lips, Petra M. Nederlof, Lodewyk F.A. Wessels, Jelle Wesseling, Marc J. van de Vijver, Elisabeth G.E. de Vries, Harm van Tinteren, Jos Jonkers, Michael Hauptmann et al. · 2014 · Breast Cancer Research
PARP1 Inhibitors: Antitumor Drug Design
Natalia V. Maluchenko, E. Yu. Kotova, Olga I. Kulaeva, Mikhail P. Kirpichnikov, V. M. Studitskiy · 2015 · Acta Naturae
PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs
Luyao Wang, Chao Liang, Fangfei Li, Daogang Guan, Xiaoqiu Wu, Xuekun Fu, Aiping Lü, Ge Zhang · 2017 · International Journal of Molecular Sciences
Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer
Xuan Jiang, Weihua Li, Xiaoying Li, Huimin Bai, Zhenyu Zhang · 2019 · Cancer Management and Research
Uncoupling of PARP1 trapping and inhibition using selective PARP1 degradation
Shuai Wang, Lei Han, Jungsoo Han, Peng Li, Qing Ding, Qing-Jun Zhang, Zhiping Liu, Chuo Chen, Yonghao Yu · 2019 · Nature Chemical Biology
CARM1 regulates replication fork speed and stress response by stimulating PARP1
Marie‐Michelle Genois, Jean‐Philippe Gagné, Takaaki Yasuhara, Jessica Jackson, Sneha Saxena, Marie-France Langelier, Ivan Ahel, Mark T. Bedford, John M. Pascal, Alessandro Vindigni et al. · 2021 · Molecular Cell
Nrf2 promotes survival following exposure to ionizing radiation
Sekhar, Konjeti R., Freeman, Michael L. · 2015 · Free Radical Biology and Medicine
Genetic Interaction Networks: Toward an Understanding of Heritability
Anastasia Baryshnikova, Michael Costanzo, Chad L. Myers, Brenda Andrews, Charles M. Boone · 2013 · Annual Review of Genomics and Human Genetics
Strategies to design clinical studies to identify predictive biomarkers in cancer research
José Luis Perez‐Gracia, Miguel F. Sanmamed, Ana Bosch, Ana Patiño‐García, Kurt Alex Schalper, Víctor Segura, Joaquim Bellmunt B, Josep M. Tabernero, Christopher J. Sweeney, Toni K. Choueiri et al. · 2016 · Cancer Treatment Reviews
Multiple roles of DNA2 nuclease/helicase in DNA metabolism, genome stability and human diseases
Li Zheng, Yuan Meng, Judith L. Campbell, Binghui Shen · 2019 · Nucleic Acids Research
ATM-Deficient Cancers Provide New Opportunities for Precision Oncology
Nicholas Jette, Mehul Kumar, Suraj Radhamani, Greydon Arthur, Siddhartha Goutam, Steven Yip, Michael Paul Kolinsky, Gareth J. Williams, Pinaki Bose, Susan P. Lees‐Miller · 2020 · Cancers
BRCA Mutations in Pancreas Cancer: Spectrum, Current Management, Challenges and Future Prospects
Winston Wong, Alexander Grenander Raufi, Rachael Ann Safyan, Susan Elaine Bates, Gulam Abbas Manji · 2020 · Cancer Management and Research
The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer
Dale W. Garsed, Ahwan Pandey, Sián Fereday, Catherine J. Kennedy, Kazuaki Takahashi, Kathryn Alsop, Phineas T. Hamilton, Joy Hendley, Yoke-Eng Chiew, Nadia Traficante et al. · 2022 · Nature Genetics
Pre-clinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers
C. Bethan Powell, Christos Mikropoulos, Stan B. Kaye, Chris M. Nutting, S. Bhide, Kate L. Newbold, Kevin Joseph Harrington · 2010 · Cancer Treatment Reviews
Going Ape as an Approach to Cancer Therapeutics
Aditi Bapat, Melissa L. Fishel, Mark R. Kelley · 2008 · Antioxidants and Redox Signaling
Integrating the DNA damage and protein stress responses during cancer development and treatment
Gorgoulis, Vassilis G, Pefani, Dafni‐Eleftheria, Pateras, Ioannis S, Trougakos, Ioannis P · 2018 · The Journal of Pathology
A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments
Mohni, Kareem N., Thompson, Petria S., Luzwick, Jessica W., Glick, Gloria G., Pendleton, Christopher S., Lehmann, Brian D., Pietenpol, Jennifer A., Cortez, David · 2015 · PLOS ONE
Requirement for Parp-1 and DNA ligases 1 or 3 but not of Xrcc1 in chromosomal translocation formation by backup end joining
Aashish Soni, Maria Siemann, Martha Grabos, Tamara Murmann-Konda, Gabriel E. Pantelias, George E. Iliakis · 2014 · Nucleic Acids Research
DNA damage response and prostate cancer: defects, regulation and therapeutic implications
Styliani Karanika, Theodoros Karantanos, Leping Li, Paul Gettys Corn, Timothy C. Thompson · 2014 · Oncogene
The role of PARP inhibition in triple-negative breast cancer: Unraveling the wide spectrum of synthetic lethality
Marios Papadimitriou, Giannis Mountzios, CHRISTOS A. PAPADIMITRIOU · 2018 · Cancer Treatment Reviews
Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer
Tamara Levin Lotan, Harsimar B. Kaur, Daniela Correia Salles, Sanjana Murali, Edward M. Schaeffer, Jerry S. S. Lanchbury, William B. Isaacs, Robert Eldon Brown, Andrea L. Richardson, Olivier Cussenot et al. · 2021 · Modern Pathology
Drug Resistance Caused by Reversion Mutation
Alan Ashworth · 2008 · Cancer Research
FIGNL1-containing protein complex is required for efficient homologous recombination repair
Jingsong Yuan, Junjie Chen · 2013 · Proceedings of the National Academy of Sciences
The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer
Johanne Ingrid Weberpals, Kyla Garbuio, Anna O'Brien, Katherine V. Clark-Knowles, Steve Paul Doucette, Olga Antoniouk, Glenwood D. Goss, Jim Dimitroulakos · 2008 · International Journal of Cancer
BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability
A. Aly, Shridar Ganesan · 2011 · Journal of Molecular Cell Biology
RING domain–deficient BRCA1 promotes PARP inhibitor and platinum resistance
Yifan Wang, John J. Krais, Andrea J. Bernhardy, Émmanuelle Nicolas, Kathy Qi Cai, Maria I. Harrell, Hyoung H. Kim, Erin M. George, Elizabeth M. Swisher, Fiona A. Simpkins et al. · 2016 · Journal of Clinical Investigation
PARP inhibitors in ovarian cancer: evidence, experience and clinical potential
Tarra Evans, Ursula A. Matulonis · 2017 · Therapeutic Advances in Medical Oncology
Berberine induces oxidative DNA damage and impairs homologous recombination repair in ovarian cancer cells to confer increased sensitivity to PARP inhibition
Dong Hou, Guangwei Xu, Caibo Zhang, Boxuan Li, Junchao Qin, Xiaohe Hao, Qiao Liu, Xiyu Zhang, Jinsong Liu, Jian‐Jun Wei et al. · 2017 · Cell Death and Disease
Triple negative breast cancer: approved treatment options and their mechanisms of action
Aditya Mandapati, Kiven Erique Lukong · 2022 · Journal of Cancer Research and Clinical Oncology